THE IMPACT OF COVID-19 PANDEMIC ON CANCER CARE IN LATIN AMERICA AND THE CARIBBEAN

A study led by the Americas Health
Foundation and supported by Roche,
assessed the impact of the pandemic on 18
key variables linked to cancer care in 11
countries across the region: Brazil, Colombia,
Ecuador, Mexico, Peru, Central America
(Costa Rica, the Dominican Republic and
Panama), and Southern Cone (Argentina,
Chile and Uruguay).

Cancer is the second leading cause of death in Latin America, accounting for more than 700 thousand deaths in 2020.


Key findings:

Provision of services for cancer care

80% of people reported interruptions in cancer care and prevention activities, due to health systems overload.

96% decrease in mammograms

due to cautionary measures such as quarantines, as well as financial limitations; these are necessary tests to detect early-stage disease.



93% of doctors reported that, at the time of diagnosis, their

advanced stage of cancer.

patients already had an

Economic impact

Nearly 50% of the total estimated economic impact is for breast cancer, representing a cost of 3.9 billion dollars.

\$5 billion dollars is the economic impact created by diagnosis and treatment delay throughout the region, according to the analysis. de texto

How to improve these results?

Governments must recognize the burden generated by the pandemic in cancer care to implement comprehensive strategies to mitigate this impact.

Governments must recognize the burden generated by the pandemic in cancer care to implement comprehensive strategies to mitigate this impact. The report sheds light on some measures that can be implemented to strengthen health systems and improve their response capacity:



Prioritize early diagnosis and timely and continued access to treatment.

Governments, patient groups and medical organizations must implement programs to prepare patients to face the new reality.

To access the full report, click on the following link.



The report was produced by medical experts and the Americas Health Foundation, EY-Parthenon and the Catalyst Consulting Group and supported by Roche, a leader in personalized healthcare and the world's largest biotech company.